Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Errors in metabolic processing of steroids resulting from inborn genetic mutations that are inherited or acquired in utero.
Biomarker and diagnostic research for steroid inherited metabolic disorder has been reported in the published literature.
No clinical trials have been registered for steroid inherited metabolic disorder.
130 publications have been identified in PubMed for steroid inherited metabolic disorder. Research spans Case Report / Case Series (20%), Basic Science / Preclinical (20%), and Epidemiology / Natural History (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 26 | 20% |
Data assembled from 2 of 12 sources · Last updated Nov 18, 2026, 8:43 AM UTC
Laboratory research
26 |
20% |
Disease patterns and progression | 26 | 20% |
Research summaries | 18 | 14% |
Clinical study results | 15 | 12% |
Testing and diagnosis research | 12 | 9% |
New treatment approaches | 7 | 5% |
Penna LS (2026). [PMID: 41489829](https://pubmed.ncbi.nlm.nih.gov/41489829/). *Hum Genet*. [Epidemiology / Natural History]
Yang Y (2026). [PMID: 41977228](https://pubmed.ncbi.nlm.nih.gov/41977228/). *Int J Mol Sci*. [Basic Science / Preclinical]
Yudiski A (2026). [PMID: 41661407](https://pubmed.ncbi.nlm.nih.gov/41661407/). *Fam Cancer*. [Review / Meta-Analysis]
Tada H (2026). [PMID: 41708459](https://pubmed.ncbi.nlm.nih.gov/41708459/). *J Clin Lipidol*. [Case Report / Case Series]
Bouwhuis N (2026). [PMID: 41793373](https://pubmed.ncbi.nlm.nih.gov/41793373/). *Journal of inherited metabolic disease*. [Clinical Trial Publication]
Mahmoud SA (2026). [PMID: 41982147](https://pubmed.ncbi.nlm.nih.gov/41982147/). *J Inherit Metab Dis*. [Basic Science / Preclinical]
Moolhuijsen LME (2026). [PMID: 42026183](https://pubmed.ncbi.nlm.nih.gov/42026183/). *Nat Genet*. [Basic Science / Preclinical]
Engström K (2026). [PMID: 42201221](https://pubmed.ncbi.nlm.nih.gov/42201221/). *Int J Neonatal Screen*. [Diagnostic / Biomarker]
Woo YH (2026). [PMID: 41750400](https://pubmed.ncbi.nlm.nih.gov/41750400/). *Biomolecules*. [Case Report / Case Series]
Waluś-Miarka M (2026). [PMID: 41794573](https://pubmed.ncbi.nlm.nih.gov/41794573/). *J Clin Lipidol*. [Case Report / Case Series]
AI-curated news mentioning steroid inherited metabolic disorder
Updated Oct 19, 2026
Government funding for biomedical ... trial efficiency in parts of Latin America. Higher rates of oncology, cardiovascular diseases, metabolic disorders, infectious diseases, and rare conditions are also expanding the volume and complexity of drug development programs. Pharmaceutical and biotechnology companies are increasing clinical research budgets to advance novel therapeutics, creating ... Government funding for biomedical research in countries such as China and Singapore is supporting regional activity, while streamlined patient recruitment is improving trial efficiency in parts of Latin America. Higher rates of oncology, cardiovascular diseases, metabolic disorders, infectious diseases, and rare conditions are also expanding the volume and complexity of drug development programs. Pharmaceutical and biotechnology companies are increasing clinical research budgets to advance novel therapeutics, creating sustained demand for manufacturing, packaging, storage, distribution, and supply chain management services. 120-Page Report Examines How Biologics, Personalized Medicine and Decentralized Trials Are Raising Demand for Cold-Chain and Just-in-Time Logistics as... According to the report, the market is expected to expand at a compound annual growth rate of 8.4% from 2026 to 2033, supported by rising research and development investments, increasing chronic disease prevalence, and the globalization of clinical trials. Growth in biologics and personalized medicine is creating demand for specialized clinical trial supply chain services. Monoclonal antibodies, cell therapies, and gene therapies require controlled storage, cold chain logistics, and precise transportation processes. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Clinical Trial Supplies Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.2. Market Restraint Analysis 3.3. Technology Landscape 3.4. Pricing Model Analysis 3.5. Tariff Impact Analysis 3.6. Value Chain Analysis 3.6.1. Supply Trends 3.6.2. Demand Trends 3.7. Market Analysis Tools 3.7.1. Porter's Five Force Analysis 3.7.2. PESTEL by SWOT Analysis
The supplied market analysis estimates ... having a genetic component and a significant proportion involving pediatric onset. Neurological disorders represent an important category within the rare-disease landscape, while oncology, hematology, metabolic disorders, pulmonary diseases, and other therapeutic areas are also attracting substantial research attention. The orphan drugs industry is evolving alongside advances in genomics, molecular biology, cell therapy, and ... The supplied market analysis estimates that approximately 6,000 to 8,000 rare diseases have been identified, with around 80% having a genetic component and a significant proportion involving pediatric onset. Neurological disorders represent an important category within the rare-disease landscape, while oncology, hematology, metabolic disorders, pulmonary diseases, and other therapeutic areas are also attracting substantial research attention. The orphan drugs industry is evolving alongside advances in genomics, molecular biology, cell therapy, and precision medicine. Pharmaceutical and biotechnology companies are expanding pipelines targeting rare cancers, neurological disorders, hematological diseases, genetic conditions, and metabolic disorders. Advances in genomics, cell therapy, gene-editing technologies, and biologics are broadening the scientific basis for developing treatments for conditions that previously had limited therapeutic options. The global orphan drugs market was valued at approximately US 195 0 billion in 2023 and is projected to grow at a CAGR of 6 9 from 2024 to 2034 reaching approximately US 424 0 billion by the end of ... Press release - Transparency Market Research - Orphan Drugs Market to Reach US$424.0 Billion by 2034 Amid Rising Rare Disease Burden and R&D Investments - TMR - published on openPR.com
A new study highlights respiratory manifestations as potential indicators for inherited metabolic disorders in children, advocating for a phenotype-driven diagnostic approach. This research could enhance early detection and treatment strategies for these rare conditions.
Ultragenyx Pharmaceutical received ... storage disease type Ia (GSDIa), the company announced on August 19, 2026.1 The approval marks the company's fifth FDA approval and its first for a gene therapy product. GSDIa is an ultra-rare, inherited metabolic disorder caused by pathogenic ... Ultragenyx Pharmaceutical received accelerated approval from the FDA for Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa), the company announced on August 19, 2026.1 The approval marks the company's fifth FDA approval and its first for a gene therapy product. GSDIa is an ultra-rare, inherited metabolic disorder caused by pathogenic variants in the gene encoding glucose-6-phosphatase, an enzyme needed to release glucose from the liver into the bloodstream.1 Without it, patients face a constant risk of severe, potentially life-threatening low blood sugar and must follow an around-the-clock regimen of raw cornstarch intake to maintain stable glucose levels. The FDA grants accelerated approval to Ultragenyx's Genglycos, the first gene therapy for GSDIa, raising manufacturing and post-market monitoring questions. The therapy also carries a boxed set of warnings common to adeno-associated virus vector gene therapies, including hypersensitivity reactions, immune-mediated liver toxicity, and adrenal insufficiency tied to the corticosteroid regimen used to manage hepatic reactions.1 Distribution will run through a national network of qualified treatment centers trained to administer the therapy, an access model increasingly used for specialized cell and gene therapy products that require infusion oversight and long-term patient monitoring beyond what a typical infusion center provides. “As our first gene therapy approval, Genglycos represents an important achievement for our company and the realization of the promise of a powerful new tool to deliver transformative medicines for people living with rare diseases,” said Eric Crombez, MD, chief medical officer, Ultragenyx, in the press release.1 That structure illustrates how sponsors of ultra-rare disease gene therapies are increasingly relying on long-term, real-world monitoring to satisfy regulators when trial populations are too small to generate conventional statistical power.
Shares of Ultragenyx Pharmaceutical RARE are rising in premarket trading today following the FDA’s accelerated approval of DTX-401, an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa).The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) ... Shares of Ultragenyx Pharmaceutical RARE are rising in premarket trading today following the FDA’s accelerated approval of DTX-401, an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa).The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) and… GSDIa is an ultra-rare inherited metabolic disorder caused by pathogenic variants in the G6PC gene. These variants lead to a deficiency of glucose-6-phosphatase, an enzyme required for the release of glucose from stored glycogen and other metabolic sources. Even with strict adherence, interruptions in treatment can expose patients to severe hypoglycemia, seizures and potentially life-threatening complications, making the disease particularly burdensome for patients and caregivers. Against this backdrop, the FDA decision is significant because Ultragenyx’s Genglycos is designed to address the underlying biological defect in GSDIa rather than manage its metabolic consequences. By delivering a functional G6PC gene to the liver, the therapy aims to restore the enzyme’s role in glucose production during fasting or metabolic stress, potentially reducing patients’ reliance on intensive cornstarch supplementation and easing the day-to-day burden of glucose management. The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) and is indicated to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients aged eight years and older with GSDIa. The approval makes Genglycos the first FDA-approved treatment designed to address the underlying cause of GSDIa and marks Ultragenyx’s first gene therapy approval and its fifth FDA approval overall. FDA Nod for RARE’s Genglycos Supported by Phase III Data